Range Biotechnologies

Range Biotechnologies is a translational proteomics company co-founded by Stanford researchers to address key bottlenecks in modern diagnostics. The company has re-engineered how proteins are detected, creating a new detection modality from the ground up that enables scalable, targeted quantification of protein biomarker panels across millions of patient samples. Its platform is designed to shift diagnostics from static population comparisons to longitudinal individual tracking, enabling proactive precision medicine for conditions like cardiovascular disease, cancer, and neurodegeneration. Range Bio provides analytical tools and platform services to longevity, liquid biopsy, and pharmacodynamics companies.